Needham & Company LLC Reaffirms “Buy” Rating for KalVista Pharmaceuticals (NASDAQ:KALV)
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a research note issued on Thursday,Benzinga reports. They presently have a $28.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 122.22% from […]
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a research note issued on Thursday,Benzinga reports. They presently have a $28.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 122.22% from […]
